Anchor brands help Pfizer deliver Q2 earnings beat

[anonymous]

Pfizer Inc. reported a rise in earnings for the second quarter, helped by the strength of its anchor brands, primarily Ibrance, Eliquis, and Xeljanz. The top and bottom lines came in above analysts’ expectations. Revenue improved by 4% driven by the continued growth of key brands, as well as biosimilars. This was partially offset by product losses of exclusivity, a decline in legacy Established Products in developed markets and ongoing legacy Hospira supply shortages. For the full year 2018, Pfizer lowered its revenue outlook while lifting its adjusted EPS guidance.

Infographics of the company's results can be found at https://news.alphastreet.com/pfizer-q2-2018-earnings-results/

 

[anonymous]

The shares fell after the company lowered its revenue outlook due to recent unfavorable change in foreign exchange rates. The stock is set to open lower on Tuesday.

 

[anonymous]

Pfizer Inc. reported a rise in earnings for the second quarter, helped by the strength of its anchor brands, primarily Ibrance, Eliquis, and Xeljanz. The top and bottom lines came in above analysts’ expectations. Revenue improved by 4% driven by the continued growth of key brands, as well as biosimilars. This was partially offset by product losses of exclusivity, a decline in legacy Established Products in developed markets and ongoing legacy Hospira supply shortages. For the full year 2018, Pfizer lowered its revenue outlook while lifting its adjusted EPS guidance.

Infographics of the company's results can be found at https://news.alphastreet.com/pfizer-q2-2018-earnings-results/

Interesting that the none of the anchors are actually Pfe drugs. Pitiful.

 

[anonymous]

The shares fell after the company lowered its revenue outlook due to recent unfavorable change in foreign exchange rates. The stock is set to open lower on Tuesday.

Same old excuses and bullshit.

 

[anonymous]

Where